Rare Disease Collaboration Harrington Discovery Institute has launched the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator and a transatlantic accelerator with a UK partner, demonstrating a proven cross-border model for rare-disease drug development. This creates opportunities for co-development, licensing discussions, and collaboration with academic, philanthropic, and investment networks.

Symposium Access The organization hosts a high-profile annual Scientific Symposium that attracts scientific leaders, Harrington Scholars, donors, and global partners, providing a direct channel to engage senior decision-makers for partnerships, sponsorships, and joint ventures.

Hospital Translational As part of University Hospitals, Harrington Discovery Institute serves as a bridge between academic discoveries and clinical development, offering pathways for translational programs and potential collaboration within a hospital-led research ecosystem.

Rare Disease Hub The Oxford-Harrington Rare Disease Centre and the transatlantic accelerator position Harrington as a hub for rare-disease therapeutic development, enabling biotech and pharma partners to co-create assets and pursue cross-border development opportunities.

Stable Funding With a solid funding foundation and ongoing revenue streams, the institute presents a resilient platform for long-term partnerships and co-funding opportunities, appealing to sponsors seeking stable collaboration windows.